Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Cos, P. en_US
dc.contributor.author Vlietinck, A. J. en_US
dc.contributor.author Vanden Berghe, D. en_US
dc.contributor.author Maes, L. en_US
dc.date.accessioned 2007-12-06T14:35:51Z
dc.date.available 2007-12-06T14:35:51Z
dc.date.issued 2006 en_US
dc.identifier.issn 0378-8741 en_US
dc.identifier.doi http://dx.doi.org/10.1016/j.jep.2006.04.003
dc.identifier.other ITG-ALB en_US
dc.identifier.other ANIMAL en_US
dc.identifier.other U-ANIMAL en_US
dc.identifier.other JIF en_US
dc.identifier.other DOI en_US
dc.identifier.other NOT AVAILABLE en_US
dc.identifier.other ABSTRACT en_US
dc.identifier.uri http://hdl.handle.net/10390/445
dc.description.abstract Natural products, either as pure compounds or as standardized plant extracts, provide unlimited opportunities for new drug leads because of the unmatched availability of chemical diversity. To secure this, a number of pivotal quality standards need to be set at the level of extract processing and primary evaluation in pharmacological screening models. This review provides a number of recommendations that will help to define a more sound 'proof-of-concept' for antibacterial, antifungal, antiviral and antiparasitic potential in natural products. An integrated panel of pathogens is proposed for antimicrobial profiling, using accessible standard in vitro experimental procedures, endpoint parameters and efficacy criteria. Primary requirements include: (1) use of reference strains or fully characterized clinical isolates, (2) in vitro models on the whole organism and if possible cell-based, (3) evaluation of selectivity by parallel cytotoxicity testing and/or integrated profiling against unrelated micro-organisms, (4) adequately broad dose range, enabling dose-response curves, (5) stringent endpoint criteria with IC(50)-values generally below 100microug/ml for extracts and below 25microM for pure compounds, (6) proper preparation, storage and in-test processing of extracts, (7) inclusion of appropriate controls in each in vitro test replicate (blanks, infected and reference controls) and (8) follow-up of in vitro activity ('hit'-status) in matching animal models ('lead'-status). en_US
dc.language English en_US
dc.subject Drug development en_US
dc.subject Anti-infective agents en_US
dc.subject Antimicrobial agents en_US
dc.subject Plant extracts en_US
dc.subject Natural products en_US
dc.subject Medicinal plants en_US
dc.subject Screening en_US
dc.title Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept' en_US
dc.type Article en_US
dc.citation.issue 3 en_US
dc.citation.jtitle Journal of Ethnopharmacology en_US
dc.citation.volume 106 en_US
dc.citation.pages 290-302 en_US
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/16698208
dc.citation.jabbreviation J Ethnopharmacol en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record